MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fphar.2021.756582

Медицинская библиотека · Frontiers in pharmacology · 2021

The Efficacy and Safety of Mirabegron for the Treatment of Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review and Meta-analysis.

Zhang Dongxu, Sun Fengze, Yao Huibao, Bao Xingjun, Wang Di, Cui Yuanshan, Wu Jitao

СтатьяОбзорПеревод в очереди

Аннотация

Background and

Objective

Over the past few years, mirabegron has been increasingly used as a therapeutic option for neurogenic lower urinary tract dysfunction. Here, we carried out a meta-analysis to investigate the efficacy and safety of mirabegron for the treatment of neurogenic lower urinary tract dysfunction.

Methods

We used a range of databases to retrieve randomized controlled trials (RCTs) relating to mirabegron in patients with neurogenic lower urinary tract dysfunction: PubMed, Embase, and Cochrane Library; our strategy conformed to the PICOS (populations, interventions, comparators, outcomes, and study designs) strategy.

Results

Our analyses involved four RCTs involving 245 patients. We found that mirabegron treatment resulted in a significant improvement in bladder compliance [mean difference (MD) = 19.53, 95% confidence interval (CI): 14.19 to 24.87, P < 0.00001], urinary incontinence episodes (MD = -0.78, 95% CI: -0.89 to -0.67, P < 0.00001) and Incontinence Quality of Life (I-QOL) (MD = 8.02, 95% CI: 3.20 to 12.84, P = 0.001). Significant differences were detected in terms of Patient Perception of Bladder Condition (PPBC) (MD = -0.54, 95% CI: -1.46 to 0.39, P = 0.26) and urinary urgency episodes (MD = -0.72, 95% CI: -3.1 to 1.66, P = 0.55). With regard to safety, there were no significant differences between mirabegron and control groups in terms of the incidence of drug-related adverse events [odds ratio (OR): 0.83, 95% CI: 0.43 to 1.59, P = 0.57], arrhythmias (OR: 1.27, 95% CI: 0.37 to 4.38, P = 0.70), hypertension (OR: 0.70, 95% CI: 0.13 to 3.82, P = 0.68), or post-voiding residual volume (MD: 1.62, 95% CI: -9.00 to 12.24, P = 0.77).

Conclusion

Mirabegron is an efficacious and safe treatment for patients with neurogenic lower urinary tract dysfunction.

Для цитирования: Zhang Dongxu, Sun Fengze, Yao Huibao, Bao Xingjun, Wang Di, Cui Yuanshan, Wu Jitao. The Efficacy and Safety of Mirabegron for the Treatment of Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review and Meta-analysis.. Frontiers in pharmacology. 2021. DOI: 10.3389/fphar.2021.756582.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.